Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the... September 20, 2018 Pink Van Makes the Rounds Throughout Rural New Zealand to Offer... February 24, 2021 Is there a right way to check your body for cancer? March 29, 2022 Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures... July 20, 2026 Load more HOT NEWS ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February Bringing a Piece of Home to the Hospital Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... High HPV Vaccination Coverage in England Associated with a Substantial Reduction...
